• Welcome to the new Inserm Transfert website
    Welcome to the new Inserm Transfert website

… Inserm Transfert, your partner for value creation and technology transfer

Inserm Transfert, specialised in technology transfer and life sciences, was founded in 2000.

It is the private subsidiary of Inserm under a Public Services Delegation agreement. The company supports Inserm research units and researchers in the process undertaken to create value from their work. Its actions are part of the translational continuum, from basic and technological to clinical research, and are used for the creation of economic and societal value.

Are you a
researcher?

Access your portal

Read more

Are you a company?

Access your portal

Read more

News press

January 24, 2017

MSD France and Lille University Regional Hospital Centre supported by Inserm Transfert sign a partnership agreement on the FREGAT Clinical-Biological database to improve the management of patients suffering from oesophago-gastric cancers.

Paris, 24 January 2017 – FREGAT (FRench Esophageal and GAastric Tumors) is the reference clinical and biological database for oesophago-gastric cancers in France. It already contains more than 1350 people listed in the database. The project intends to include…
January 05, 2017

“SANOFI-INSERM HBV Cure program”: a medical, academic and pharmaceutical alliance for research into hepatitis B

Paris, France - 5 January 2017 – Inserm and Sanofi have joined forces and efforts in a…
December 20, 2016

Jean-Laurent Casanova, specialist in genetics of infectious diseases, winner of the Inserm Grand Prix 2016 prize.

The annual Inserm prize ceremony on 8 December at the Collège de France will showcase 8…
Our technology offer
Read more
Our strategic innovation domains
Read more
1555
PATENT FAMILIES
14
MILLIONS OF EUROS EXPENDITURE IN MATURATION
400
NUMBER OF CONTRACTS AND LICENSES DETECTED
300
PROJECTS DETECTED
* For the year 2016
ILiAD
ILiAD
The Team run by Camille Locht, Inserm Research Director and Director of Inserm U1019, located in the Pasteur Institute in Lille, has developed an attenuated strain of Bordetella pertussis with the...
SILTISS
SILTISS
The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the George Winter Prize from the European Biomaterials Society, has developed a...
MEDIMMUNE
MEDIMMUNE
Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several therapeutic areas, including oncology,...
COHORTES
COHORTES
INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving human beings (in particular, cohorts,...
prev
next
ILiAD
ILiAD
The Team run by Camille Locht, Inserm Research Director and Director of Inserm U1019, located in the Pasteur Institute in Lille, has developed an attenuated strain of Bordetella pertussis with the aim of developing a new effective vaccination vector against various pathogens,  
SILTISS
SILTISS
The Team run by Didier Letourneur, CNRS Research Director and Director of Inserm U1148, located in Paris and awarded the George Winter Prize from the European Biomaterials Society, has developed a natural biocompatible hydrogel which is biodegradable
MEDIMMUNE
MEDIMMUNE
Since 2011, MedImmune, the AstraZeneca international biological substances unit, has contributed to the advancement of Inserm laboratory research in several therapeutic areas, including oncology, respiratory and inflammatory diseases and autoimmune diseases.  
COHORTES
COHORTES
INSERM TRANSFERT has developed unique expertise in the development and negotiation of public/private partnerships (PPP) linked to research projects involving human beings (in particular, cohorts, biobanks and clinical studies).
IMMUNOSCORE
IMMUNOSCORE
IMMUNOSCORE® measures the density of two T lymphocyte populations – CD8 and CD3 – which are found within and at the periphery of tumours.
prev
next